MDXH (MDxHealth) Valuation Rank


MDXH MDxHealth SA MDXH
45 GF Score
Price $0.51
GF Value $2.20
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is MDxHealth Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

MDxHealth Valuation Rank Related Terms

MDXH
45GF Score
MDxHealth SA MDXH
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is MDxHealth (MDXH) Overvalued in 2026?

Based on GuruFocus' analysis, MDxHealth stock appears to be undervalued. The current stock price of $0.51 is trading 76.9% below its estimated GF Value™ of $2.20. GuruFocus considers MDxHealth to be Possible Value Trap.

Key valuation signals for MDXH:

  • Valuation Rank:
  • GF Value™: $2.20 vs. price of $0.51 (76.9% below fair value)
  • GF Score™: 45/100 with 5 warning signs

No single metric tells the full story. See the MDXH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

MDxHealth Business Description

Other Exchanges O6C1:Germany
Address Zone Industrielle des Hauts-Sarts, Rue d’Abhooz, 31, Cap Business Center, Herstal, Liege, BEL, 4040
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.
45GF Score

Get the complete analysis for MDXH

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.51
Price
$2.20
GF Value